Phreesia (PHR) to Release Quarterly Earnings on Wednesday

Phreesia (NYSE:PHR) is anticipated to release its earnings data after the market closes on Wednesday, March 12th. Analysts expect Phreesia to post earnings of ($0.19) per share and revenue of $108.93 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The business had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. During the same quarter last year, the business posted ($0.58) earnings per share. The company’s quarterly revenue was up 16.6% on a year-over-year basis. On average, analysts expect Phreesia to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Phreesia Trading Down 7.5 %

Shares of NYSE PHR opened at $21.90 on Tuesday. The business has a fifty day simple moving average of $27.38 and a 200-day simple moving average of $24.00. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -14.89 and a beta of 1.03. Phreesia has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Analysts Set New Price Targets

PHR has been the subject of several research analyst reports. Citigroup lifted their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Robert W. Baird cut their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Truist Financial boosted their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $31.15.

Insider Activity at Phreesia

In other Phreesia news, SVP David Linetsky sold 11,853 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $24.85, for a total value of $294,547.05. Following the completion of the sale, the senior vice president now directly owns 188,354 shares of the company’s stock, valued at $4,680,596.90. This represents a 5.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Balaji Gandhi sold 3,195 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $85,018.95. Following the completion of the sale, the chief financial officer now owns 148,509 shares in the company, valued at $3,951,824.49. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 195,740 shares of company stock worth $5,441,409 in the last 90 days. 5.80% of the stock is owned by company insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.